DeepMed Research

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

18F-DCFPyL PET/CT in Hepatocellular Carcinoma

Phase 2

Completed

Conditions: Hepatocellular Carcinoma

Interventions: Drug: F18-FDG
Device: MRI
Device: CT
Drug: F18-DCFPyL

First Posted Date: 2021-08-18

Last Posted Date: 2025-03-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 7

Registration Number: NCT05009979

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Hepatocellular Carcinoma (HCC)

Phase 1

Recruiting

Conditions: Hepatocellular Carcinoma
Hepatocellular Cancer
Metastatic Hepatocellular Carcinoma

Interventions: Drug: Cyclophosphamide
Biological: CAR-T cell
Drug: Fludarabine

First Posted Date: 2021-08-13

Last Posted Date: 2025-05-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 38

Registration Number: NCT05003895

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma

Phase 2

Recruiting

Conditions: Peritoneal Malignant Mesothelioma

Interventions: Biological: Atezolizumab
Biological: Bevacizumab
Procedure: Biospecimen Collection
Drug: Carboplatin
Procedure: Computed Tomography
Procedure: Cytoreductive Surgery
Drug: Hyperthermic Intraperitoneal Chemotherapy
Drug: Pemetrexed
Procedure: Positron Emission Tomography

First Posted Date: 2021-08-12

Last Posted Date: 2025-04-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 66

Registration Number: NCT05001880

Locations: 🇺🇸
Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸
Carle at The Riverfront, Danville, Illinois, United States

and more 36 locations

Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer

Phase 2

Withdrawn

Conditions: Stage IIB Lung Cancer AJCC v8
Lung Non-Small Cell Carcinoma
Superior Sulcus Lung Carcinoma
Stage IIIA Lung Cancer AJCC v8

Interventions: Biological: Atezolizumab
Procedure: Biopsy
Procedure: Biospecimen Collection
Drug: Carboplatin
Procedure: Computed Tomography
Drug: Cisplatin
Drug: Etoposide
Radiation: External Beam Radiation Therapy
Procedure: Magnetic Resonance Imaging
Drug: Paclitaxel
Drug: Pemetrexed
Procedure: Positron Emission Tomography
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2021-08-04

Last Posted Date: 2023-09-26

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT04989283

Locations: 🇺🇸
Community Medical Hospital, Missoula, Montana, United States
🇺🇸
The Mark H Zangmeister Center, Columbus, Ohio, United States
🇺🇸
Rush - Copley Medical Center, Aurora, Illinois, United States

and more 43 locations

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

Phase 2

Recruiting

Conditions: Sporadic Papillary Renal Cell Carcinoma
Stage IV Renal Cell Cancer AJCC v8
Hereditary Leiomyomatosis and Renal Cell Carcinoma
Renal Cell Carcinoma
Papillary Renal Cell Carcinoma
Stage III Renal Cell Cancer AJCC v8

Interventions: Biological: Atezolizumab
Biological: Bevacizumab
Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Bone Scan
Procedure: Computed Tomography
Procedure: Computed Tomography with Contrast
Drug: Erlotinib
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography
Drug: Sodium Fluoride F-18

First Posted Date: 2021-07-29

Last Posted Date: 2025-04-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 65

Registration Number: NCT04981509

Locations: 🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Emory Saint Joseph's Hospital, Atlanta, Georgia, United States

and more 9 locations

Natural History Study of Parathyroid Disorders

Recruiting

Conditions: Inheritable Bone Diseases
Parathyroid Cancer
Pseudohypoparathyroidism
Primary Hyperparathyroidism
Multiple Endocrine Neoplasia, Type 1

First Posted Date: 2021-07-21

Last Posted Date: 2025-05-15

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 3000

Registration Number: NCT04969926

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Natural History of KSHV-Associated Multicentric Castleman s Disease

Recruiting

Conditions: Multicentric Castleman s Disease

First Posted Date: 2021-07-20

Last Posted Date: 2025-04-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 195

Registration Number: NCT04968288

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy

Phase 1

Recruiting

Conditions: Locally Advanced Bladder Urothelial Carcinoma
Locally Advanced Urethral Urothelial Carcinoma
Locally Advanced Urothelial Carcinoma
Metastatic Bladder Urothelial Carcinoma
Locally Advanced Renal Pelvis Urothelial Carcinoma
Locally Advanced Ureter Urothelial Carcinoma
Metastatic Renal Pelvis Urothelial Carcinoma
Metastatic Ureter Urothelial Carcinoma
Metastatic Urothelial Carcinoma
Stage IIIB Bladder Cancer AJCC v8

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Scan
Procedure: Computed Tomography
Procedure: Echocardiography Test
Drug: Enfortumab Vedotin
Drug: Erdafitinib
Procedure: Multigated Acquisition Scan

First Posted Date: 2021-07-15

Last Posted Date: 2025-04-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT04963153

Locations: 🇺🇸
NYP/Weill Cornell Medical Center, New York, New York, United States
🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States

and more 7 locations

Needs Assessment for Individuals and Families Affected by Dyskeratosis Congenita (DC) and Related Telomere Biology Disorders (TBD)

Completed

Conditions: Dyskeratosis Congenita
Telomere Biology Disorders

First Posted Date: 2021-07-13

Last Posted Date: 2024-12-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 53

Registration Number: NCT04959188

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies

Phase 1

Recruiting

Conditions: Hematologic Neoplasms

Interventions: Drug: Mycophenolate Mofetil
Procedure: Allogeneic HSCT
Drug: Fludarabine
Drug: Sirolimus
Drug: Filgrastim
Drug: Cyclophosphamide
Drug: Mesna
Procedure: Total Body Irradiation (TBI)

First Posted Date: 2021-07-13

Last Posted Date: 2025-05-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 320

Registration Number: NCT04959175

Locations: 🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy